Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current treatment options in systemic Sclerosis (Scleroderma).

G H Stummvoll1

  • 1Division of Rheumatology, Department of Internal Medicine III, University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna. Georg.Stummvoll@akh-wien.ac.at

Acta Medica Austriaca
|March 20, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pristane-induced lupus as a model of human lupus arthritis: evolvement of autoantibodies, internal organ and joint inflammation.

Lupus·2013
Same author

Autoantibodies against CD74 in spondyloarthritis.

Annals of the rheumatic diseases·2013
Same author

Immunoadsorption (IAS) for systemic lupus erythematosus.

Lupus·2011
Same author

Immunoadsorption for systemic lupus erythematosus.

Atherosclerosis. Supplements·2010
Same author

Immunoadsorption in SLE: three different high affinity columns are adequately effective in removing autoantibodies and controlling disease activity.

Atherosclerosis. Supplements·2010
Same author

Characterisation of cellular and humoral autoimmune responses to histone H1 and core histones in human systemic lupus erythaematosus.

Annals of the rheumatic diseases·2008
Same journal

[Gestational diabetes mellitus].

Acta medica Austriaca·2005
Same journal

[Diagnosis, therapy and follow-up of diabetic eye diseases].

Acta medica Austriaca·2005
Same journal

[Diabetic nephropathy].

Acta medica Austriaca·2005
Same journal

[The diabetic foot].

Acta medica Austriaca·2005
Same journal

[Diabetic neuropathy].

Acta medica Austriaca·2005
Same journal

[Inhibition of platelet aggregation].

Acta medica Austriaca·2005
See all related articles

Systemic Sclerosis (SSc), or Scleroderma, is a complex autoimmune disease with unknown causes. While treatments for the overall condition remain challenging, specific organ manifestations can be managed effectively.

Area of Science:

  • Immunology
  • Rheumatology
  • Autoimmune Diseases

Background:

  • Systemic Sclerosis (SSc), or Scleroderma, is a generalized autoimmune disorder affecting skin and organs.
  • Its etiology and pathogenesis are largely unknown, though T lymphocytes are implicated.
  • The disease's rarity, diverse manifestations, and variable course present significant therapeutic challenges.

Purpose of the Study:

  • To review current therapeutic options for Systemic Sclerosis.
  • To discuss investigated immunomodulatory agents and their effectiveness.
  • To highlight successful treatments for specific organ manifestations.

Main Methods:

  • Literature review of current therapeutic strategies for SSc.
  • Analysis of data on immunomodulatory agents used in SSc treatment.

Related Experiment Videos

  • Examination of treatment outcomes for organ-specific manifestations.

    • Main Results:

    • No single immunomodulatory agent has proven consistently effective for overall SSc.
    • Extracorporeal therapies and stem cell transplantation are under investigation.
    • Life-threatening manifestations like interstitial pneumonitis and renal crisis show treatable responses.

    Conclusions:

    • Effective treatment for the overall course of Systemic Sclerosis remains elusive.
    • Targeted therapies for organ-specific complications offer improved patient outcomes.
    • Further research into immunomodulatory agents and novel treatments is warranted.